ALX Oncology Holdings Inc. announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. Mr. Jeff Knight, age 55, served as the Chief Development and Operating Officer at Crinetics Pharmaceuticals Inc., a global biopharmaceutical company, from September 2021 to April 2026. From October 2018 to August 2021, Mr. Knight served as Senior Vice President, Portfolio Management and Corporate Operations at Poseida Therapeutics Inc., where he was responsible for portfolio management and strategy, alliance management, quality and compliance, and corporate operations.
From March 2017 until October 2018, he was Vice President, Development Operations and Project and Portfolio Management at Halozyme Therapeutics Inc. From July 2015 until March 2017, he served as Executive Director, Global Development Operations at Amgen Inc. and from January 2012 until July 2015, Mr. Knight served in various program and portfolio management and development operations roles at Onyx Pharmaceuticals. Prior to that, he held several leadership roles of increasing responsibility in clinical operations, regulatory affairs, and project management at Genentech, PRA International, and Hoechst Marion Roussel (now Sanofi). Mr. Knight earned a Master?s of Public Health in biostatistics and epidemiology from the University of Oklahoma Health Sciences Center and a B.A. in psychology from the University of Oklahoma.
He also earned a B.S. in nursing from the University of Kansas.
